A comprehensive, evidence-based guide to GLP-1–based obesity medications — the mechanism of action, what the clinical trials actually show, the muscle question, and what you need to do while you’re on them.
This guide is for educational purposes only. It does not constitute medical advice and is not a substitute for consultation with a qualified physician or healthcare provider. GLP-1 medications are prescription drugs. All decisions about starting, continuing, or stopping medication should be made with your prescribing physician.
Glucagon-like peptide-1 (GLP-1) is a hormone your body already makes. It is produced in the small intestine in response to eating and travels to the brain, pancreas, and stomach, where it performs three key jobs: it signals the brain that you are full, it slows the rate at which food leaves the stomach, and it stimulates the pancreas to release insulin in response to glucose.
The problem is that natural GLP-1 breaks down in the bloodstream within minutes. GLP-1–based obesity medications include semaglutide (Ozempic, Wegovy), a GLP-1 receptor agonist, and tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist. They are engineered to mimic these hormone signals but resist breakdown, keeping the signal active for days at a time. The result is a sustained reduction in appetite, a quieting of what many patients describe as constant "food noise," and a meaningful decrease in calorie intake without the white-knuckle willpower effort that traditional dieting requires.
Tirzepatide adds a second mechanism: it also activates the GIP receptor (glucose-dependent insulinotropic polypeptide), which amplifies the metabolic effects and produces greater weight loss than GLP-1 agonism alone.
The STEP trial program for semaglutide and the SURMOUNT program for tirzepatide represent the largest, most rigorous weight-loss drug trials ever conducted. The results were unlike anything seen before in obesity pharmacology — weight reductions that previously required bariatric surgery.
| Medication | Trial | Duration | Mean Weight Loss | Responders ≥5% |
|---|---|---|---|---|
| Semaglutide 2.4mg | STEP-1 | 68 weeks | −14.9% | 86% |
| Semaglutide 2.4mg | STEP-4 | 68 weeks | −17.4% (continued) | — |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | −20.9% | 91% |
| Tirzepatide 10mg | SURMOUNT-1 | 72 weeks | −19.5% | 89% |
| Oral semaglutide 25mg / Wegovy tablet | OASIS-4 / FDA Study 7 | 64 weeks | −13.6% | 76.3% |
| Semaglutide 7.2mg / Wegovy HD | STEP UP / FDA Study 8 | 72 weeks | −18.8% | 88.7% |
| Orforglipron 17.2mg / Foundayo | ATTAIN-1 / FDA Trial 1 | 72 weeks | −11.1% | 71.5% |
Trial percentages are averages, not guaranteed individual outcomes. Trial populations, durations, doses, designs, and statistical estimands differ; where practical, this table uses the principal FDA-label, intention-to-treat, or treatment-regimen-style estimate for consistency. These separate trials are not a direct head-to-head ranking. Under current FDA labeling, Wegovy 7.2 mg may be used in adults who have tolerated 2.4 mg for at least four weeks and for whom additional weight reduction is clinically indicated.
These are not average results for the average person — they are averages across large trial populations. Individual responses vary considerably. Some people lose significantly more; others lose less. The medication reduces appetite and food intake, but it does not override energy balance. Calories still count. The medication makes it easier to eat less — it does not do the work for you.
"GLP-1 medications reduce hunger. They don't build your system. The window while you're on them is the most important window you'll ever have."
— The Diet RebelLast reviewed: August 12, 2026
This is a status snapshot, not a treatment recommendation or a forecast. Candidate medicines can advance, change dose plans, receive different regulatory decisions, or fail to reach the market. The practical point is that the obesity-treatment landscape is broadening beyond today’s familiar brands, while the evidence for each candidate still needs to be read in the context of its own trial design and population.
| Candidate | Status | Evidence and context |
|---|---|---|
| Retatrutide Triple GIP/GLP-1/glucagon receptor agonist | Investigational — not FDA-approved Once weekly; Lilly plans a U.S. submission in Q1 2027. | Positive pivotal Phase 3 results have been reported from TRIUMPH-1, -2, and -3; additional studies continue. In TRIUMPH-1, 12 mg reached −28.3% at 80 weeks under the efficacy estimand; the treatment-regimen estimate was about −25.0%. This is a trial-specific average, not a universal expectation. Reuters reported a limited expanded-access pathway for a small number of qualifying adults unable to join an appropriate trial. Expanded access is exceptional and does not make retatrutide FDA-approved, commercially available, or routinely prescribable. |
| CagriSema Semaglutide + cagrilintide (an amylin analogue) | Under FDA review for obesity — not yet FDA-approved Novo Nordisk currently expects a U.S. decision in Q4 2026. | In REDEFINE-1, Novo Nordisk reports 22.7% weight loss under a trial-product/efficacy-style analysis. The expected decision window is company guidance, not a guaranteed approval date. |
| Aleniglipron Once-daily oral small-molecule GLP-1 receptor agonist | Investigational — not FDA-approved Phase 3 ACCOMPLISH program underway. | Structure Therapeutics reported first patients dosed in ACCOMPLISH-1 and ACCOMPLISH-2 in August 2026. In ACCESS II, the 180 mg dose reported up to 16.3% placebo-adjusted mean body-weight loss at 44 weeks. |
These candidates are not interchangeable with currently approved medicines. Retatrutide and aleniglipron remain investigational, and CagriSema remains under FDA review. A Phase 3 result, an expanded-access report, or a company decision window does not establish routine availability, individual suitability, or a guaranteed outcome. The reported percentage changes come from different studies with different populations, doses, durations, and estimands; they should not be read as a direct ranking of what one medicine will do for a particular person.
The clinical evidence on discontinuation is consistent and unambiguous. Without the habits and skills to support the lower weight, most of the weight comes back.
The most important thing to understand about GLP-1 medications is what happens when they stop. In the STEP-1 extension study, participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. After switching to placebo at week 36, SURMOUNT-4 participants regained 14.0% of body weight from week 36 to week 88; those who continued tirzepatide lost an additional 5.5%.
This is not a failure of the medication. It reflects the biology of obesity: when the pharmacological appetite suppression is removed, the physiological drive to eat returns. Hunger comes back. Food noise returns. The body's set point — the weight it has been defending for years — reasserts itself.
Real-world data reinforce this picture. Studies of insurance claims and electronic health records show that 50–65% of adults prescribed GLP-1 medications for obesity discontinue within the first year, due to cost, side effects, injection burden, or access issues. For most of these patients, the weight returns.
The medication is a tool. The habits are the infrastructure. Without the infrastructure, the tool cannot hold the result.
One of the most common concerns about GLP-1 medications is muscle loss. The concern is legitimate — but the evidence puts it in context.
In the STEP-1 trial, about 40% of the weight lost with semaglutide was lean mass and 60% was fat mass. In the SURMOUNT-1 trial with tirzepatide, about 26% of the weight lost was lean mass and 74% was fat mass. These proportions are consistent with what is observed during diet-induced weight loss generally — they are not unique to GLP-1 medications.
Researchers at Mass General Brigham reviewed the available data and concluded: "GLP-1s are one tool of many for weight loss. It's important to allay fears and provide reassurance that some lean body mass loss is a part of the weight loss journey, and we have tools to help." Importantly, muscle quality — measured by fat infiltration into muscle tissue — may actually improve during GLP-1 therapy, as shown in MRI substudy data from the SURPASS-3 trial.
The risk of clinically meaningful muscle loss is greatest in older adults, people who lose weight rapidly, those with low protein intake, and those who are sedentary. The solution is not to avoid the medication — it is to use the medication alongside the practices that protect muscle.
"Combining a high-protein diet and consistent exercise with GLP-1 treatment has the greatest benefit in preserving bone and muscle mass, compared to diet alone or high-protein diet alone."
— Mass General Brigham Grand Rounds, 2025Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — are the most common and are typically most pronounced during dose escalation. Most people find that symptoms improve significantly once they reach a stable dose. Eating smaller meals, avoiding high-fat foods, and eating slowly all help reduce GI discomfort.
Serious risks include pancreatitis; postmarketing reports have also included ileus and intestinal obstruction. GLP-1 medications carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). These are conversations to have with your prescribing physician before starting.
Reduced appetite can also lead to inadequate protein and micronutrient intake if you are not intentional about what you eat. Eating less is the goal — but eating less of the right things matters. This is where tracking becomes essential, not optional.
| Side Effect | Frequency | When It Typically Occurs | Management |
|---|---|---|---|
| Nausea | Very common | Dose escalation phase | Smaller meals, slow eating, avoid fatty foods |
| Constipation | Common | Ongoing | Adequate hydration, fiber, movement |
| Diarrhea | Common | Early in treatment | Usually self-resolving |
| Fatigue | Common | Early weeks | Adequate protein and sleep |
| Reduced appetite | Very common | Throughout treatment | Intentional eating — prioritize protein |
Your physician manages the medication. The Diet Rebel builds everything else. Here is what that means in practice.
The medication reduces your appetite. It does not tell you how much you are actually eating. Tracking your calorie intake — using a food logging app — gives you the data you need to understand your energy balance, ensure you are in a deficit, and avoid the common trap of eating too little protein while eating too few calories overall.
Aim for 0.7–1.0 grams of protein per pound of body weight per day. This is the most important nutritional lever for preserving muscle during weight loss. With reduced appetite, protein is often the first macronutrient to fall short — which is exactly when it matters most.
Two to three sessions per week of resistance training is the most effective strategy for preserving lean mass during a calorie deficit. You do not need to train like an athlete. You need to give your muscles a reason to stay. Progressive overload — gradually increasing the challenge over time — is the mechanism that drives adaptation.
The scale is data. Daily fluctuations are noise — water, sodium, digestion, hormones. The weekly average is the signal. Track it, trend it, and use it to make decisions. Do not let a single number on a single morning derail a week of good work.
The medication is suppressing your appetite. Use this window — when food is less emotionally charged, when hunger is quieter, when decision fatigue is lower — to build the skills that will outlast the medication. Learn to navigate social eating. Learn your calorie targets. Build a movement habit. These are the things that determine what happens after the prescription ends.
Coaching that works alongside your GLP-1 prescription — calorie targets, protein strategy, resistance training, and the skills to keep the weight off when the medication ends.
Free 30-minute consult · No obligation. · No long-term commitment.